Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

Mindful Self-Compassion for Anxiety Disorders and Depression

Not Applicable

Recruiting

Conditions: Panic Disorder
Agoraphobia
Anxiety Disorders
Social Phobia
Major Depressive Disorder
Generalized Anxiety Disorder
Social Anxiety Disorder

Interventions: Behavioral: Mindful Self-Compassion

First Posted Date: 2023-01-04

Last Posted Date: 2024-06-07

Lead Sponsor: Georgetown University

Target Recruit Count: 40

Registration Number: NCT05671419

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
KRAS Mutation-Related Tumors

Interventions: Drug: NEROFE
Drug: Doxorubicin

First Posted Date: 2022-12-22

Last Posted Date: 2024-03-12

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT05661201

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BXCL701
Drug: Pembrolizumab

First Posted Date: 2022-09-29

Last Posted Date: 2023-08-21

Lead Sponsor: Georgetown University

Target Recruit Count: 43

Registration Number: NCT05558982

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

Phase 1

Active, not recruiting

Conditions: Safety Issues
Pain
Pancreas Fibrosis

Interventions: Drug: Placebo
Drug: Proglumide

First Posted Date: 2022-09-23

Last Posted Date: 2024-02-01

Lead Sponsor: Georgetown University

Target Recruit Count: 32

Registration Number: NCT05551858

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Phase 3

Recruiting

Conditions: Adenocarcinoma of Biliary Tract
Colon Adenocarcinoma
Rectal Adenocarcinoma
Pancreatic Adenocarcinoma
Gastric Adenocarcinoma
Hepatocellular Carcinoma
Gallbladder Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2022-08-01

Last Posted Date: 2024-12-18

Lead Sponsor: Georgetown University

Target Recruit Count: 20

Registration Number: NCT05482516

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer Stage IV
Ovarian Cancer Stage 3
Ovarian Cancer Stage III

Interventions: Biological: NY-ESO-1 Peptide vaccine
Drug: Toripalimab-tpzi

First Posted Date: 2022-07-29

Last Posted Date: 2024-12-02

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT05479045

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

A Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship

Not Applicable

Recruiting

Conditions: Health Care Utilization
Adherence, Patient
Health Knowledge, Attitudes, Practice
Survivorship
Childhood Cancer

Interventions: Behavioral: Multi-level Intervention of shared model of survivorship care
Other: Comparison Group

First Posted Date: 2022-07-07

Last Posted Date: 2024-07-18

Lead Sponsor: Georgetown University

Target Recruit Count: 240

Registration Number: NCT05448560

Locations: 🇺🇸
Children's Hospital Colorado, Denver, Colorado, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of North Carolina Children's Hospital, Chapel Hill, North Carolina, United States

and more 1 locations

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Phase 1

Recruiting

Conditions: Cancer Related Cognitive Decline
Non-metastatic Breast Cancer

Interventions: Drug: TTP488
Drug: ddAC/ddT
Drug: TC
Drug: TCHP
Drug: Chemotherapy regimen that includes ddAC

First Posted Date: 2022-02-25

Last Posted Date: 2024-04-24

Lead Sponsor: Georgetown University

Target Recruit Count: 48

Registration Number: NCT05256745

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

CONTIGO - Informing Latinas About HBOC Risk

Not Applicable

Conditions: Hereditary Breast and Ovarian Cancer

Interventions: Behavioral: FORCE Fact Sheet

First Posted Date: 2021-11-23

Last Posted Date: 2023-08-14

Lead Sponsor: Georgetown University

Target Recruit Count: 332

Registration Number: NCT05130606

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Pediatric Boot Camp Program

Not Applicable

Recruiting

Conditions: Type 1 Diabetes
Children, Only

Interventions: Other: telehealth visits

First Posted Date: 2021-10-04

Last Posted Date: 2021-10-04

Lead Sponsor: Georgetown University

Target Recruit Count: 32

Registration Number: NCT05066893

Locations: 🇺🇸
Medstar Pediatrics, Washington, District of Columbia, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy